CURIO RAISES INVESTMENT FOR WOMEN’S MENTAL HEALTH
The announcement comes on the heels of Curio’s recent 510(k) clearance from the US Food and Drug Administration (FDA) for its prescription digital therapeutic device, MamaLift Plus, as a symptomatic treatment for postpartum depression (PPD).